SVRA News and Press, Savara Inc. From 05/09/24

2024-05-09 17:27:25 ET More on Savara JMP starts Savara at buy, cites market potential for lung disease drug Seeking Alpha’s Quant Rating on Savara Historical earnings data for Savara Financial information for Savara Read the full article on ...

Pivotal Phase 3 IMPALA-2 Trial Remains On-track, Top Line Results Expected by End of 2Q 2024 48-week placebo-controlled trial is evaluating molgramostim nebulizer solution (molgramostim), a novel inhaled biologic, for the treatment of autoimmune Pulmonary Alveolar Proteinosis (aPAP), a ra...

Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that its management team will participate in a fireside chat at the Citizens JMP Life Science Conference on May 14, 2024 at 6:00am PT/9:00am ET. A live webcast of the fir...

2024-04-18 16:56:16 ET Gainers: Travere Therapeutics ( TVTX ) +6% . Sabre Corporation ( SABR ) +5% . Nextracker  ( NXT ) +3% . Cipher Mining  ( CIFR ) +3% . BioCryst Pharmaceuticals ( BCRX ) +3% . Losers: Avidit...

Savara’s Partner, Trillium Health LLC, to Present Data on the Laboratory Blood Test for Diagnosing aPAP Company to Host Industry Theater on Pulmonary Alveolar Proteinosis (PAP) with Two World-Renowned Experts Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage ...

2024-03-07 17:29:34 ET More on Savara JMP starts Savara at buy, cites market potential for lung disease drug Seeking Alpha’s Quant Rating on Savara Historical earnings data for Savara Financial information for Savara Read the full article on ...

Remains On-Track to Report Top Line Data from the Pivotal Phase 3 IMPALA-2 Trial by End of 2Q 2024 48-week placebo-controlled trial is evaluating molgramostim nebulizer solution (molgramostim), a novel inhaled biologic, for the treatment of autoimmune Pulmonary Alveolar Proteinosis (aPAP)...

Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that its management team will participate in a fireside chat at the Barclays 26th Annual Global Healthcare Conference on March 14, 2024 at 5:00am PT/8:00am ET. A live web...

Savara Inc. (NASDAQ: SVRA) has caught the attention of the investment community today with its bullish price action. The company's shares have moved 4.49% on the day to $5.35. Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. Its lead product candid...

2024-02-15 13:15:06 ET More on Savara Seeking Alpha’s Quant Rating on Savara Historical earnings data for Savara Financial information for Savara Read the full article on Seeking Alpha For further details see: JMP starts Savara at buy, cite...